Holen Sie sich die Stockscreener-App
6.76
16.35%
0.95
Handel nachbörslich:
6.93
0.17
+2.51%
Schlusskurs vom Vortag:
$5.81
Offen:
$6.075
24-Stunden-Volumen:
11.36M
Relative Volume:
3.72
Marktkapitalisierung:
$1.92B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-125.04M
KGV:
-8.2439
EPS:
-0.82
Netto-Cashflow:
$-122.99M
1W Leistung:
+88.30%
1M Leistung:
+104.85%
6M Leistung:
+338.96%
1J Leistung:
+145.82%
1-Tages-Spanne:
$5.73
$6.85
1-Wochen-Bereich:
$3.36
$6.85
52-Wochen-Spanne:
$1.01
$6.85
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Vergleichen Sie ERAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
6.76 | 1.65B | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Erasca Stock Surges Amid Merger Talks and Positive Analyst Ratings - StocksToTrade
Why Erasca Inc. stock appeals to analystsJuly 2025 Opening Moves & Accurate Entry and Exit Point Alerts - ulpravda.ru
Risk Analysis: Why Erasca Inc stock is favored by pension fundsNew Guidance & Proven Capital Preservation Tips - moha.gov.vn
Erasca’s general counsel Garner sells $670,812 in shares By Investing.com - Investing.com India
Erasca’s general counsel Garner sells $670,812 in shares - Investing.com
Assessing Erasca (ERAS) Valuation After FDA Trial Hold And New ERAS-0015 Patent - simplywall.st
How geopolitical tensions affect Erasca Inc. stockTrend Reversal & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Rate Cut: How Erasca Inc. stock responds to policy changesPortfolio Gains Report & Smart Swing Trading Alerts - ulpravda.ru
Is Erasca Inc. stock a buy for dividend growth2025 Volatility Report & Low Risk Investment Opportunities - ulpravda.ru
What's Going With Cancer Biotech Erasca Stock On Thursday? - Benzinga
Erasca price target raised to $2 from $1 at BofA - MSN
Erasca Stock Pre-Market (-14%) : FDA Places Partial Clinical Hold on ERAS-4001 Trial - Trefis
What's Happening With Cancer Biotech Erasca Shares This Thursday? - Bitget
Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines - TipRanks
Erasca stock pulls back after 25% jump, Stifel cites competitor data By Investing.com - Investing.com Canada
Erasca stock pulls back after 25% jump, Stifel cites competitor data - Investing.com India
Erasca Inc stock hits 52-week high at $3.80 - Investing.com
Erasca Inc stock hits 52-week high at $3.80 By Investing.com - Investing.com Nigeria
User | custercountychief.comErasca, Inc.Common Stock (Nasdaq:ERAS) Stock Quote - FinancialContent
Erasca initiated with an Overweight at Piper Sandler - TipRanks
Piper Sandler initiates Erasca stock with Overweight rating, $5 price target - Investing.com UK
Upcoming EventsErasca, Inc.Common Stock (Nasdaq:ERAS) Stock Quote - FinancialContent
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
BPASErasca, Inc.Common Stock (Nasdaq:ERAS) Stock Quote - FinancialContent
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
B of A Securities Upgrades Erasca (ERAS) - MSN
Fund Flows: How geopolitical tensions affect Erasca Inc stock2025 Market Sentiment & Real-Time Price Movement Reports - moha.gov.vn
Erasca (NASDAQ:ERAS) Trading Up 4.1% – Should You Buy? - Defense World
Aug Spikes: How Erasca Inc stock responds to policy changesJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - moha.gov.vn
Erasca (ERAS) Valuation Check After S&P Biotechnology Select Industry Index Inclusion - Yahoo Finance
Did Index Inclusion and New RAS Patent Just Shift Erasca's (ERAS) Investment Narrative? - simplywall.st
Are Erasca Inc (ERAS) shares a good deal now? - uspostnews.com
Erasca, Inc.(NasdaqGS: ERAS) added to S&P Biotechnology Select Industry Index - marketscreener.com
Treasury Yields: Is Erasca Inc stock a buy on dipsWeekly Profit Summary & AI Powered Market Entry Strategies - moha.gov.vn
Why Erasca Inc. stock could be next big winnerWeekly Loss Report & Stock Portfolio Risk Management - Улправда
Will Erasca Inc. stock remain a Wall Street favoritePortfolio Update Summary & Risk Controlled Swing Trade Alerts - Улправда
Buyback Watch: Is Erasca Inc. stock a buy on dipsMarket Activity Summary & Daily Chart Pattern Signals - DonanımHaber
Aug Weekly: How Erasca Inc. stock responds to policy changesJuly 2025 Momentum & Free Long-Term Investment Growth Plans - DonanımHaber
Momentum Shift: Why Erasca Inc. stock could be next big winner2025 Geopolitical Influence & Comprehensive Market Scan Reports - Улправда
Erasca (ERAS) Valuation Check After ERAS-0015 Patent Extension and New Chief Scientific Officer Appointment - simplywall.st
Erasca Inc stock hits 52-week high at $3.68 - Investing.com India
Shareholder Erasca Foundation Files To Sell 8,333 Of Erasca Inc [ERAS] - TradingView — Track All Markets
Erasca Inc stock hits 52-week high at $3.68 By Investing.com - Investing.com Nigeria
Erasca (ERAS) Extends ERAS-0015 Patent to 2043 and Strengthens RAS Pipeline Momentum - simplywall.st
Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks - simplywall.st
Erasca price target raised to $5 from $4 at Mizuho - MSN
Aug Breakouts: Is Erasca Inc stock a buy for dividend growthEarnings Growth Report & AI Optimized Trading Strategy Guides - moha.gov.vn
Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results - MSN
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Erasca, Inc Secures U.S. Patent Protection Through 2043 for ERAS-0015 - marketscreener.com
Mizuho Maintains Erasca (ERAS) Outperform Recommendation - Nasdaq
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):